GlassScriptPhysician profile
Ricky R Byrd
NPI 1992865752
$3,031.20
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $652 · 2021: $542 · 2022: $551 · 2023: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $630.51 | 2019-2023 | Calquence |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.64 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $499.11 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $195.61 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $156.98 | 2019-2021 | |
| Abbvie INC. | $153.27 | 2019-2023 | Ubrelvy |
| Biocryst US Sales Co., LLC | $76.70 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.13 | 2022 | |
| Abbott Laboratories | $65.22 | 2023 | Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $56.21 | 2020-2022 | |
| Innocoll Pharmaceuticals Limited | $55.68 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $50.91 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $50.65 | 2021 | |
| Eisai INC. | $46.46 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.37 | 2023 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $29.64 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $29.49 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $28.33 | 2019-2020 | |
| Exact Sciences Corporation | $27.81 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $27.46 | 2023 | Repatha |
| Glaxosmithkline, LLC. | $20.31 | 2023 | Arexvy, Shingrix |
| Pfizer INC. | $19.85 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $17.75 | 2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $16.20 | 2019 | |
| Dexcom, INC. | $15.76 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $14.95 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $14.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.71 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $10.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricky Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.